Comment highlights survival outcomes in stage II-III melanoma, suggesting improved risk management and treatment assessment.
This comment discusses Marjanovic et al.’s study on stage II-III melanoma survival paradox, focusing on two key aspects: the need for refined assessment of comorbidity severity and treatment disparities, and the validation of staging misclassification and micrometastasis biology. These insights aim to enhance the clinical implications of the original study and inform optimized risk-adapted management for stage II-III melanoma patients.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: